Abstract
The main aim of the study was to evaluate the patients' glycemic control and adherence to self-care tasks. Patients with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes of the adult (LADA) using a multiple daily injection (MDI) regimen with carbohydrate counting (n = 25, Subgroup B) or fixed insulin dose (n = 25, Subgroup C) were allocated to use the application (app) for 12 weeks. Both subgroups were compared with each other and against a control group (n = 25, Group A) comprising patients with T1DM or LADA treated with continuous subcutaneous insulin infusion (CSII) in a parallel-group, open-label, clinical treatment trial. All patients had glycated hemoglobin (A1C) levels measured and were asked to fill out the Diabetes Self-Management Profile (DSMP) questionnaire at study start and end. The patients were instructed to measure capillary glucose six times daily in study weeks 4, 8, and 12. Mean A1C levels decreased 0.725% in Subgroup C in intragroup analysis (p = 0.0063), and had a mean variation of 0.834% compared with Group A (p = 0.003). Mean DSMP scores increased 5.77 points in Subgroup B in intragroup analysis (p = 0.0004) and increased by a mean of 6.815 points in relation to Group A (p = 0.002). OneTouch Reveal improved both A1C levels and DSMP scores in patients with T1DM or LADA compared with standard treatment (CSII).
Highlights
A2019 projection from the International Diabetes Federation (IDF) ranked Brazil third among all countries in highest number of cases of type 1 diabetes mellitus (T1DM), with an estimated prevalence of 51,500 cases among children and adolescents [1]
This study focused on the glycemic control and adherence to self-care tasks of patients with T1DM or latent autoimmune diabetes of the adult (LADA) treated with an multiple daily injection (MDI) regimen using the OneTouch Reveal self-monitoring application versus standard treatment (CSII, control group)
The present study showed that the use of a blood glucose meter synchronized to the OneTouch Reveal mobile phone app improved both A1C levels and Diabetes Self-Management Profile (DSMP) scores in patients with T1DM or LADA compared with standard treatment (CSII)
Summary
A2019 projection from the International Diabetes Federation (IDF) ranked Brazil third among all countries in highest number of cases of type 1 diabetes mellitus (T1DM), with an estimated prevalence of 51,500 cases among children and adolescents [1]. Adherence in diabetes and a mobile app goals [2]. Complications of T1DM can be prevented by strict patient adherence to self-care tasks and achievement of intensive glycemic control [3]. Adherence to treatment of chronic diseases is lower than 50% [5,6,7,8] and requires three additional medical visits per patient per year, increasing the average annual cost of individual treatment by $2,000 [6]. For optimal adherence in diabetes, the patients must follow difficult treatment regimens. Patients with T1DM and some of those with latent autoimmune diabetes of the adult (LADA) must be treated with continuous subcutaneous insulin infusion (CSII) or with multiple daily injection (MDI) regimens of fixed insulin doses or insulin doses conditioned to carbohydrate counting [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
